KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence

Sponsor hopes to demonstrate that FDA's process for reviewing extended-release abuse-deterrent opioids may not be appropriate for an immediate-release product. Apadaz would be the first immediate-release opioid with an abuse-deterrent claim if approved.

chess

KemPharm Inc. is taking to FDA's dispute resolution process to resolve a complete response letter it received in June pertaining to Apadaz, its candidate for acute pain, arguing that current FDA standards for abuse-deterrent analgesic drugs are intended for extended-release formulations but perhaps not sufficient for immediate-release products.

In tandem with that Sept. 15 announcement, the Coralville, Iowa, firm also pushed back the expected timeline to launch for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards